This story has been updated from a previous version to reflect a more accurate head count of ASMS attendees.

ASMS 2004, held this week in Nashville, Tenn., was not quite the mass spec release party that it has been in previous years. In fact, only Bruker Daltonics and Waters released new mass specs at the 5,300-person event. Instead, consumables and chromatography headed the bill, with life science mass spec vendors scrambling to promote smaller, application-focused releases targeted overwhelmingly at biomarker discovery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.